Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2023—Vistapath has introduced its flagship product, the Sentinel pathology processing platform. The platform uses machine vision combined with artificial intelligence to assess specimens and create a gross report in a few seconds. It consists of the Sentinel module, which measures 17 in. W × 12 in. D × 15 in. H, and the touchscreen, which measures 15 in. W × 8 in. D × 11 in. H.
January 2023—PerkinElmer announced that the FDA has authorized the marketing of its Eonis SCID-SMA assay kit for in vitro diagnostic use by certified laboratories for the detection of spinal muscular atrophy and severe combined immunodeficiency in newborns. This is the first FDA-authorized assay for SMA screening in newborns in the United States, the company says, and is part of the company’s Eonis platform. The Eonis platform is a robust, flexible system that uses real-time PCR technology to screen for SMA and SCID using a single dried blood spot sample.
February 2023—BD has introduced a robotic track system for the BD Kiestra microbiology laboratory solution that automates lab specimen processing. The BD Kiestra third-generation total lab automation system allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra modules.
February 2022—Qiagen has launched its EZ2 Connect MDx for use in diagnostic laboratories. The platform enables labs to purify DNA and RNA from up to 24 samples at the same time in as few as 30 minutes and uses magnetic-bead technology to extract nucleic acids from blood plasma, serum, stool, and other sample types. The benchtop instrument automatically pierces sealed cartridges, heats samples for incubation, and automates pipetting of beads, buffers, and enzymes. It can be used in research or IVD mode and monitored and managed remotely using the QIAsphere app.
February 2023—Agilent Technologies announced a partnership with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics. The agreement aims to deliver an end-to-end multiplex solution integrating Agilent’s Dako Omnis staining instrument and Akoya’s PhenoImager HT imaging platform.
February 2023—SD Biosensor and SJL Partners LLC, both based in South Korea, have completed the transaction to acquire Meridian Bioscience. Meridian will continue to operate as an independent entity, under new ownership, headquartered in Cincinnati. Meridian offers immunoassay and molecular raw materials for human and veterinarian diagnostics testing, and it plans to add service capabilities for lyophilized bead and lateral flow test manufacturing.
February 2023—Thermo Fisher Scientific announced the FDA has granted emergency use authorization for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA kit, a polymerase chain reaction test designed to detect non-variola orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours. The test is intended for the qualitative detection of DNA from monkeypox virus (clades one and two) and screening for non-variola orthopoxviruses in human lesion swab specimens from patients suspected of monkeypox infection by their health care provider. The test is for in vitro diagnostic use.
February 2023—Agilent Technologies announced an agreement with Quest Diagnostics that will enable providers and patients in the United States to access the Agilent Resolution ctDx First liquid biopsy next-generation sequencing test.
January 2023—Verichem Laboratories offers liquid-stable, ready-to-use clinical reference materials intended for calibration and calibration verification procedures for total cholesterol and high- and low-density lipoprotein assays.
January 2023—DiaSorin announced it has received FDA 510(k) clearance for its Simplexa Congenital CMV Direct kit. The molecular diagnostic test enables direct detection of cytomegalovirus DNA in saliva swab and urine specimens from babies 21 days old or younger. It is the first kit to receive FDA clearance for CMV detection from both saliva swab and urine specimens.
